Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

FEMJA transplatation

Phase 2Biologic

HHospices Civils de Lyon

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Limbal Stem Cell DeficiencyRecruiting

Limbal Stem Cell DeficiencyPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2031

Phase 1/2Recruiting

Limbal Stem Cell Deficiency

NCT03949881

Clinical

Trials by Indication[1]

Limbal Stem Cell Deficiency1 trial

Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency

Recruiting·HHospices Civils de Lyon·Phase 1/2·NCT03949881·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FEMJA transplatation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FEMJA transplatation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FEMJA transplatation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: HHospices Civils de Lyon

Related News